HUE039368T2 - Kristályos pirimidin származékok szuszpenziói kapszulákban - Google Patents

Kristályos pirimidin származékok szuszpenziói kapszulákban

Info

Publication number
HUE039368T2
HUE039368T2 HUE06831479A HUE06831479A HUE039368T2 HU E039368 T2 HUE039368 T2 HU E039368T2 HU E06831479 A HUE06831479 A HU E06831479A HU E06831479 A HUE06831479 A HU E06831479A HU E039368 T2 HUE039368 T2 HU E039368T2
Authority
HU
Hungary
Prior art keywords
capsules
suspensions
pyrimidine nucleoside
nucleoside derivatives
crystalline pyrimidine
Prior art date
Application number
HUE06831479A
Other languages
English (en)
Inventor
Robert Westwood
Alistair Selkirk
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of HUE039368T2 publication Critical patent/HUE039368T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE06831479A 2005-12-23 2006-12-22 Kristályos pirimidin származékok szuszpenziói kapszulákban HUE039368T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0526419.7A GB0526419D0 (en) 2005-12-23 2005-12-23 Formulation

Publications (1)

Publication Number Publication Date
HUE039368T2 true HUE039368T2 (hu) 2018-12-28

Family

ID=35841215

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06831479A HUE039368T2 (hu) 2005-12-23 2006-12-22 Kristályos pirimidin származékok szuszpenziói kapszulákban

Country Status (17)

Country Link
US (1) US8497291B2 (hu)
EP (1) EP1962814B1 (hu)
JP (2) JP5443763B2 (hu)
CN (1) CN101346132B (hu)
AU (1) AU2006327951B2 (hu)
BR (1) BRPI0620229B8 (hu)
CA (1) CA2633308C (hu)
DK (1) DK1962814T3 (hu)
ES (1) ES2672106T3 (hu)
GB (1) GB0526419D0 (hu)
HK (1) HK1126412A1 (hu)
HU (1) HUE039368T2 (hu)
IL (1) IL192348A (hu)
PT (1) PT1962814T (hu)
RU (1) RU2428972C2 (hu)
TR (1) TR201808182T4 (hu)
WO (1) WO2007072061A2 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4446661B2 (ja) 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、17α位に環状エステル基を有するアンドロスタンの17β−カルボチオ酸エステル誘導体
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2587381T3 (es) * 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
NZ589719A (en) 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
CN102414216B (zh) * 2009-05-15 2015-01-21 德鲁塔负富莱制药股份有限公司 1-(2’-氰基-2’-脱氧-β-D-阿拉伯呋喃糖基)胞嘧啶一盐酸盐的稳定型结晶
KR101830142B1 (ko) 2010-06-02 2018-02-20 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 경구 투약 형태
US10226478B2 (en) 2011-04-14 2019-03-12 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法
US9872874B2 (en) 2012-05-15 2018-01-23 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
ES2748562T3 (es) * 2013-02-28 2020-03-17 Basf As Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma
CN106963742B (zh) * 2016-11-07 2021-02-23 澳门大学 中药固液胶囊及其制备方法
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100191774B1 (ko) * 1991-04-22 1999-06-15 오스카 아끼히꼬 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
CA2079413C (en) * 1991-09-30 2003-09-09 Masakatsu Kaneko Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
KR19980073479A (ko) * 1997-03-14 1998-11-05 한스루돌프하우스, 니콜케르커 사이클로스포린-함유 연질캅셀제
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
JP3748536B2 (ja) * 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
JP2005531495A (ja) * 2001-12-21 2005-10-20 シャイア ラボラトリーズ,インコーポレイテッド 高い物理的安定性を有する経口カプセル製剤
JP5096658B2 (ja) * 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
US20050249802A1 (en) * 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
JP2013189463A (ja) 2013-09-26
JP5443763B2 (ja) 2014-03-19
WO2007072061A3 (en) 2007-10-25
US20090074856A1 (en) 2009-03-19
WO2007072061A2 (en) 2007-06-28
BRPI0620229B1 (pt) 2020-09-15
BRPI0620229A2 (pt) 2011-11-01
RU2008130411A (ru) 2010-01-27
HK1126412A1 (en) 2009-09-04
EP1962814B1 (en) 2018-04-25
AU2006327951A1 (en) 2007-06-28
CN101346132B (zh) 2013-01-16
ES2672106T3 (es) 2018-06-12
BRPI0620229B8 (pt) 2021-05-25
CA2633308A1 (en) 2007-06-28
CN101346132A (zh) 2009-01-14
EP1962814A2 (en) 2008-09-03
IL192348A (en) 2016-02-29
BRPI0620229A8 (pt) 2018-01-02
JP2009520797A (ja) 2009-05-28
AU2006327951B2 (en) 2012-09-06
US8497291B2 (en) 2013-07-30
PT1962814T (pt) 2018-06-22
DK1962814T3 (en) 2018-08-06
IL192348A0 (en) 2009-08-03
TR201808182T4 (tr) 2018-07-23
CA2633308C (en) 2014-06-17
GB0526419D0 (en) 2006-02-08
RU2428972C2 (ru) 2011-09-20

Similar Documents

Publication Publication Date Title
HK1126412A1 (en) Crystalline pyrimidine nucleoside derivatives suspensions in capsules
AP2008004486A0 (en) Pyrimidine derivatives
GB0525080D0 (en) Pyrimidine derivatives
HK1203488A1 (en) Pyrimidine substituted purine derivatives
GB0525083D0 (en) Pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
IL192610A0 (en) Pyrimidine derivatives
IL181386A0 (en) Pyrimidine derivatives
GB0525081D0 (en) Pyrimidine derivatives
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
GB0614579D0 (en) Pyrimidine derivatives
IL179914A0 (en) Pyrimidine derivatives
ZA200804958B (en) Antiviral nucleosides
GB0415364D0 (en) Pyrimidine derivatives
HRP20140377T1 (en) Pyrimidine derivatives
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
IL186939A0 (en) Pyrimidine derivatives and their use as
IL195018A0 (en) Piperidinyl pyrimidine derivatives
ZA201000107B (en) Pyrimidine derivatives 934
IL184779A0 (en) Novel pyrimidine nucleoside compound or salt thereof
GB0415367D0 (en) Pyrimidine derivatives
PL1951730T3 (pl) Pochodne pirymidyny połączone przez grupy heteroalkilowe
GB0505786D0 (en) A2b adenosine receptor antagonists